Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stock

Lynx1 Capital Management LP, a 10% owner and director of Korro Bio, Inc. (NASDAQ:KRRO), recently acquired common stock in the company totaling $884,751. The purchases, which occurred over several days in late October 2026, involved shares bought at weighted average prices ranging from $9.6764 to $12.1061 per share, increasing the investment firm’s stake in the biotechnology company. The timing of these purchases coincides with a strong rally in KRRO shares, which posted a 35% return over the past week, bringing the current stock price to $12.02. According to InvestingPro data, the stock has shown significant volatility with a beta of 2.36, and the platform offers 10 additional ProTips for investors analyzing this biotechnology company.

The transactions involved the acquisition of 79,809 shares of Korro Bio common stock.

On October 22, 2026, Lynx1 Capital Management LP purchased two blocks of shares: 12,175 shares at a weighted average price of $9.6764, with individual prices for these shares ranging from $9.54 to $9.8550. An additional 40,000 shares were acquired on the same day at a weighted average price of $11.0366, with individual prices ranging from $10.955 to $11.11.

Further acquisitions took place on October 23, 2026, when 2,510 shares were bought at a weighted average price of $12.1061, with prices for these shares falling between $11.9250 and $12.3500. The final reported transaction was on October 26, 2026, with the purchase of 25,124 shares at a weighted average price of $11.7454, with prices ranging from $11.7450 to $11.80.

These securities are held indirectly by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP serves as the investment manager. Weston Nichols, the sole member of Lynx1 Capital Management GP LLC (the general partner of the investment manager), disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Following these transactions, Lynx1 Capital Management LP beneficially owns 1,624,789 shares of Korro Bio common stock.

In other recent news, Korro Bio has made significant strides in its clinical development programs. The company announced that it has dosed the first cohort of participants in its Phase 1/2 clinical trial for KRRO-121. This trial is part of the global ANCHOR trial program, focusing on the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. H.C. Wainwright has reiterated a Buy rating for Korro Bio, maintaining a price target of $15.00, following this development.

Meanwhile, Raymond James has reiterated an Outperform rating with a price target of $23.00, driven by the company’s expansion into hyperammonemia indications. Korro Bio plans to initiate the first in-human clinical study for KRRO-121 in the second half of 2026, pending regulatory approval later this year. These developments reflect the company’s ongoing efforts to advance its pipeline in treating serious metabolic disorders.